Clinical pharmacology and therapeutics
Axatilimab Immunogenicity and Clinical Relevance in Patients with Chronic Graft-Versus-Host Disease.
Yan-Ou Yang, Xing Liu, Breann Barker, Xuecheng Zhang, Peter Ordentlich
Published: 202510.1002/cpt.70161
Abstract
Axatilimab, a monoclonal antibody targeting colony-stimulating factor 1 (CSF-1) receptor, is approved in the US for the treatment of chronic graft-versus-host disease (cGVHD) after failure of ≥2 lines of systemic therapy. In this study, the effects o…
Preview only. Read the full abstract at the source